Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of study patients

From: Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study

Characteristics Valuesa (n = 49)
Age (yr) 11.5 (4–17)
Sex [females, n (%)] 33 (67.3 %)
Weight (kg) 41 (13.4–119.7)
Height (cm) 146 (95–178)
MTX weekly dose (mg) 13.75 (7.5–20)
MTX weekly dose (mg/kg) 0.31 (0.08–0.67)
MTX weekly dose (mg/m2)b 10.2 (4.1–15.5)
Number of medications prescribed 5 (1–8)
Number of side effects recorded 3 (1–2)
Pain scalec 0.9 (0–7.1)
General evaluation scalec 0.5 (0–8.2)
CMAS scored 51.5 (42–55)
  1. aValues represent median (range), except where indicated otherwise
  2. bSurface area was calculated using the Mosteller method [59]
  3. cPain scale and general evaluation scores were obtained from the patients’ Childhood Health Assessment Questionnaire
  4. dChildhood Myositis Assessment Scale (CMAS) score was recorded for children with JDM